Status:
TERMINATED
To Evaluate the Impact of PET/CT on Radiation Treatment Planning in Relation to Changes in GTV in Stage 3 NSCLC
Lead Sponsor:
University of Manitoba
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Acknowledging that level I evidence already exists regarding the general beneficial impact on FDG PET in the staging and subsequent management of lung cancer the investigators postulate that fusing PE...
Detailed Description
Primary objectives of the study: 1.To determine the impact of PET/CT fusion on gross tumor volume ( GTV ) for primary(GTVP) and nodal (GTVN) disease for each patient by comparing GTV contours using t...
Eligibility Criteria
Inclusion
- Patients must be eligible for the Oncology FDG PET Winnipeg PET Program/Edmonton Cross Cancer Institute Extended Phase III Clinical Trial - Protocol 001, and in addition;
- Pathologically proven NSCLC
- Clinical stage III A (inoperable) or stage IIIB where there is intent to pursue radical curative RT/chemo, staged with conventional imaging as outlined in standard work up section.
- ECOG Performance status 0-2
- Age ≥ 18 years
- FEV1 ≥ 1.0 L
- No prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for one year or more for non primary bronchogenic cancers and two years for primary bronchogencic cancers;
- No prior RT to thorax.
- Must be able to start RT within 4 weeks after PET/CT simulation
- Participants may be treated with radical radiation only or without concurrent chemotherapy, adjuvant chemotherapy or neo-adjuvant therapy.
Exclusion
- As per Oncology FDG PET Winnipeg PET Program/Edmonton Cross Cancer Institute Extended Phase III Clinical Trial - Protocol 001 and more specifically:
- Unable/unwilling to give informed consent.
- Uncontrolled hyperglycemia ( Blood sugar\> 12 mmol/L)
- Pregnant or lactating females
Key Trial Info
Start Date :
April 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT01888692
Start Date
April 1 2007
End Date
December 1 2010
Last Update
June 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Care Manitoba
Winnipeg, Manitoba, Canada, R3E0V9